New immunotherapy drug Keytruda approved by FDA to fight 'tough-to-treat' breast cancer
Keytruda, developed by Merck & Co Inc, has been given FDA approval to be used to combat TNBC. The rare form of breast cancer appears in 10 to 15 percent of women who are diagnosed. (Source: the Mail online | Health)
Source: the Mail online | Health - July 27, 2021 Category: Consumer Health News Source Type: news

Protein may predict response to immunotherapy in breast cancer, study finds
The presence of a specific molecule in breast cancer tumors may serve as an indicator of potential response to treatment with immunotherapy drugs, a study published by Clinical Cancer Research found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 27, 2021 Category: Consumer Health News Source Type: news

Umoja Biopharma Expands Management Team with Key Hires in Research and Business Development
SEATTLE, July 27, 2021 -- (Healthcare Sales & Marketing Network) -- Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of so... Biopharmaceuticals, Personnel Umoja Biopharma, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 27, 2021 Category: Pharmaceuticals Source Type: news

Covid vaccines confirmed to cause Parkinson's, dementia symptoms
(Natural News) Former National Institutes of Health (NIH) contract scientist and Classen Immunotherapies proprietor J. Bart Classen has published a paper warning that there is strong potential for Wuhan coronavirus (Covid-19) mRNA “vaccines” to trigger Parkinson’s, dementia and a variety of other prion and chronic diseases. Alzheimer’s, amyotrophic lateral sclerosis (ALS), and multiple system atrophy... (Source: NaturalNews.com)
Source: NaturalNews.com - July 26, 2021 Category: Consumer Health News Source Type: news

PET/CT shows promise predicting outcomes in head, neck cancer
PET/CT imaging may help predict outcomes in patients on immunotherapy for hea...Read more on AuntMinnie.comRelated Reading: Total-body PET/CT scanner in the works Theragnostics, German hospital to study THG-008 for PET PET radiomics tailor head/neck cancer treatment RT + immunotherapy = head/neck cancer treatment option CT lung screening can catch recurring head, neck cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 23, 2021 Category: Radiology Source Type: news

CAR T-Cell Therapy Showing Promise with Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center continues its drive toward a future that may involve innovative CAR T-cell therapy as part of standard-of-care treatment for malignant pleural mesothelioma. The latest step was a clinical trial exploring a first-in-human, intrapleural-administered CAR T-cell therapy used in combination with pembrolizumab, a well-known immunotherapy drug also known by the brand name Keytruda. Results were impressive, including a 23.9-month median overall survival and an 83% one-year survival rate for patients. Cancer Discovery published the single-center study results July 15. “There is ...
Source: Asbestos and Mesothelioma News - July 22, 2021 Category: Environmental Health Authors: Chris Elkins Source Type: news

Rensselaer-designed platform could enable personalized immunotherapy
(Rensselaer Polytechnic Institute) An innovative testing platform that more closely mimics what cancer encounters in the body may allow for more precise, personalized therapies by enabling the rapid study of multiple therapeutic combinations against tumor cells. The platform, which uses a three-dimensional environment to more closely mirror a tumor microenvironment, is demonstrated in research published in Communications Biology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 22, 2021 Category: International Medicine & Public Health Source Type: news

Advanced bladder cancers respond to immunotherapy regardless of gene mutation status
(UNC Lineberger Comprehensive Cancer Center) UNC Lineberger researchers and colleagues report a study has demonstrated that patients with advanced bladder cancers whose tumors have a mutated FGFR3 gene respond to immunotherapy in a manner that is similar to patients without that mutation. This discovery runs counter to previous research that suggested FGFR3-mutated bladder cancers should not be treated with immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2021 Category: Cancer & Oncology Source Type: news

ASCO 2021: Best Lung Cancer IO Data ASCO 2021: Best Lung Cancer IO Data
Pooled analysis supports chemo + immunotherapy for patients with PD-L1 1%-49%; immunosuppressants for adverse effects of immunotherapy; and AI predicts outcomes better than pathologic exam.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 21, 2021 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

New Drug Combination Shows Promise for Peritoneal Mesothelioma
Researchers at MD Anderson Cancer Center in Houston have uncovered a new, promising treatment option for patients with peritoneal mesothelioma, potentially filling a gaping void that exists today. The immunotherapy drug combination of Tecentriq and Avastin, known generically as atezolizumab and bevacizumab, respectively, showed unusual efficacy in a recent study of 20 patients with this rare cancer. Although some patients have previously found significant success and extended survival with the cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combination, or HIPEC, those with unresectable disease ha...
Source: Asbestos and Mesothelioma News - July 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Monkeys May Lead the Way for Immunotherapy HIV Cure Monkeys May Lead the Way for Immunotherapy HIV Cure
Mindful of the pitfalls of previous monkey studies on HIV, the researchers designed the trial to make it difficult for the drug combination to show better results than might be realistic in humans.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 21, 2021 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Mark Foundation funds Jackson Laboratory scientists to study immunotherapy side effects
(The Mark Foundation for Cancer Research) The Mark Foundation for Cancer Research announces a $1 million grant to The Jackson Laboratory to study the relationship between genetics and the harmful side effects of cancer immunotherapy using mice engineered with humanized immune systems. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 20, 2021 Category: Cancer & Oncology Source Type: news

Personalized immunotherapy response studied in body-on-a-chip cancer models
(Wake Forest Baptist Medical Center) Wake Forest researchers and clinicians are using patient-specific tumor 'organoid' models as a preclinical companion platform to better evaluate immunotherapy treatment for appendiceal cancer, (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 19, 2021 Category: Cancer & Oncology Source Type: news

Cross-Resistance: One Cancer Therapy Can Undermine the Next
Targeted cancer therapy may jeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples. (Source: The Scientist)
Source: The Scientist - July 16, 2021 Category: Science Tags: News & Opinion Source Type: news

ctDNA Identifies Patients Who Benefit From Immunotherapy in MIUC ctDNA Identifies Patients Who Benefit From Immunotherapy in MIUC
For patients with muscle-invasive urothelial carcinoma (MIUC), detectable ctDNA after surgery is a marker of poor prognosis and of response to the immunotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Low-dose radiotherapy combined with immunotherapy eradicates metastatic cancer in mice
(University of Pittsburgh) More doesn't necessarily mean better - including in cancer treatment. University of Pittsburgh School of Medicine and University of Wisconsin-Madison scientists report today in Science Translational Medicine that combining targeted radiopharmaceutical therapy with immunotherapy significantly boosts eradication of metastatic cancer in mice, even when the radiation is given in doses too low to destroy the cancer outright. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news

Mesothelioma Research Grants Focus on Immunotherapy
This study will start with comparisons in tumor-bearing animals treated with immunotherapy. Future drug targets will be based on the differences that are found. The goal is to find drugs that can prevent side effects while preserving robust anti-tumor response. The post Mesothelioma Research Grants Focus on Immunotherapy appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - July 12, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Hummingbird Bioscience and MD Anderson Announce Strategic Research Collaboration To Advance Innovative Immunotherapies
Multi-year collaboration will investigate and evaluate Hummingbird's HMBD-002 VISTA antagonist antibody HOUSTON and SINGAPORE, July 12, 2021 -- (Healthcare Sales & Marketing Network) -- Hummingbird Bioscience, an innovative clinical-stage biotech compa... Biopharmaceuticals, Oncology Hummingbird Bioscience, Rational Antibody Discovery (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 12, 2021 Category: Pharmaceuticals Source Type: news

MD Anderson and Hummingbird Bioscience announce strategic research collaboration to advance innovative immunotherapies
(University of Texas M. D. Anderson Cancer Center) MD Anderson and Hummingbird Bioscience announced a multi-year strategic research collaboration to investigate HMBD-002, Hummingbird's VISTA antagonist antibody, as a novel immunotherapy for cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 12, 2021 Category: Cancer & Oncology Source Type: news

'Tumor avatars' predict patients' response to immunotherapy
(Netherlands Cancer Institute) Tumor fragments in the lab are able to predict whether the corresponding real-life patients will benefit from immunotherapy. " We've solved a major problem many scientists had been facing: preserving a tumors original composition and structure outside of the patient in the lab " , says cancer researcher Daniela Thommen from the Netherlands Cancer Institute. On 8 July, the results of her study are published in Nature Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 8, 2021 Category: Cancer & Oncology Source Type: news

Potential marker for success of immunotherapy in the treatment of lung cancer
(Medical University of Vienna) Lung cancer has the highest mortality rate of all cancers, and treatment options are extremely limited, especially for patients with oncogenic mutations in the KRAS gene. Some patients respond very well to treatment with immune checkpoint inhibitors while it is completely ineffective in others. A MedUni Vienna research group identified a potential marker for the success of immunotherapy in lung cancer patients and explained the underlying molecular processes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 8, 2021 Category: Cancer & Oncology Source Type: news

Sublingual Immunotherapy: Where Does It Stand? Sublingual Immunotherapy: Where Does It Stand?
Published data and real-world experience are growing for this food allergy treatment.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 7, 2021 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news

Tislelizumab Benefit in HCC Undimmed by Prior Therapies Tislelizumab Benefit in HCC Undimmed by Prior Therapies
Patients with advanced hepatocellular carcinoma (HCC) can achieve durable responses, and overall survival is"encouraging" with the novel immunotherapy, even after multiple prior therapies.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 6, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New cancer findings can give wider access to immunotherapy
(Karolinska Institutet) Researchers at Karolinska Institutet in Sweden publish new findings in the journal Cancer Discovery showing how pharmacological activation of the protein p53 boosts the immune response against tumours. The results can be of significance to the development of new combination therapies that will give more cancer patients access to immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 6, 2021 Category: Cancer & Oncology Source Type: news

Hymenoptera venom immunotherapy: immune mechanisms of induced protection and tolerance - Dem šar Luzar A, Korošec P, Kosnik M, Zidarn M, Rijavec M.
Hymenoptera venom allergy is one of the most severe allergic diseases, with a considerable prevalence of anaphylactic reaction, making it potentially lethal. In this review, we provide an overview of the current knowledge and recent findings in understandi... (Source: SafetyLit)
Source: SafetyLit - July 5, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Structures discovered in brain cancer patients can help fight tumors
(Uppsala University) Researchers at Uppsala University have discovered lymph node-like structures close to the tumour in brain cancer patients, where immune cells can be activated to attack the tumour. They also found that immunotherapy enhanced the formation of these structures in a mouse model. This discovery suggests new opportunities to regulate the anti-tumour response of the immune system. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 5, 2021 Category: International Medicine & Public Health Source Type: news

Closer to cure: New imaging method tracks cancer treatment efficacy in preclinical studies
(The National Institutes for Quantum and Radiological Science and Technology) Several cancers grow through immunosuppression, making immunotherapy a promising approach to treating cancers. But several approaches against one highly sought-after target molecule for such treatment have failed in late stage clinical trials. To find out why, scientists will need to study what happens to the target molecule over time once the treatment is administered. Now, in a game-changer for this field, a team from Japan has discovered a new PET-imaging-based method to achieve this tracking. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 2, 2021 Category: Cancer & Oncology Source Type: news

Cancer: Immunotherapies without side effects?
(Universit é de Gen è ve) Immunotherapy has revolutionized the field of cancer treatment. However, inflammatory reactions in healthy tissues frequently trigger side effects that can be serious. Scientists (UNIGE/Harvard Medical School) have succeeded in establishing the differences between deleterious immune reactions and those targeting tumor cells that are sought after. It appears that while the immune mechanisms are similar, the cell populations involved are different. This work makes it possible to envisage targeted and less dangerous treatments for cancer patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 2, 2021 Category: Cancer & Oncology Source Type: news

Abcuro, ImaginAb tout Immuno-PET study results
Abcuro and ImaginAb are highlighting the results of a study using the Immuno-PE...Read more on AuntMinnie.comRelated Reading: ImaginAb lands $13M in growth funding ImaginAb, Pfizer ink deal on PET agent ImaginAb touts research on T-cell PET imaging agent ImaginAb touts study at immunotherapy meeting (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 30, 2021 Category: Radiology Source Type: news

Machine learning helps in predicting when immunotherapy will be effective
(Eindhoven University of Technology) Cancer cells can put the body's immune cells into sleep mode. Immunotherapy can reverse this, but it doesn't work for all patients and all cancer types. Researchers at TU/e have developed machine learning models that can predict if someone is likely to respond positively to immunotherapy. In clinical settings, this could pave the way for personalized immunotherapy approaches for patients, as well as guidance on how to best combine immunotherapy with other treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 30, 2021 Category: International Medicine & Public Health Source Type: news

Top Abstracts in Locally Advanced NSCLC From ASCO 2021 Top Abstracts in Locally Advanced NSCLC From ASCO 2021
Dr Thomas Stinchcombe discusses key data on locally advanced NSCLC from ASCO 2021, including results of atezolizumab as adjuvant therapy and chemotherapy plus immunotherapy in the neoadjuvant setting.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 29, 2021 Category: Consumer Health News Tags: None ReCAP Source Type: news

GPS Vaccine Plus Opdivo Shows Promise for Pleural Mesothelioma
A novel, targeted cancer vaccine combined with the immunotherapy drug Opdivo has shown surprising efficacy for mesothelioma patients whose disease no longer responds to standard chemotherapy. In a phase I clinical trial at Memorial Sloan Kettering Cancer Center, the galinpepimut-S vaccine, also known as GPS, has produced an impressive, anti-tumor synergy with Opdivo, based upon early data. GPS targets the WT1 protein, which is expressed in high levels of various cancers but rarely seen in normal adult cells. The protein has been especially resistant to standard chemotherapy. The vaccine works by inducing a powerfu...
Source: Asbestos and Mesothelioma News - June 29, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Cell-based immunotherapy shows promise against melanoma
(Washington University School of Medicine) Researchers at Washington University School of Medicine in St. Louis have shown in preclinical studies conducted in mice and human cells that a type of immunotherapy based on natural killer cells could be effective against solid tumors, starting with melanoma, a type of skin cancer that can be deadly if not caught early. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 29, 2021 Category: International Medicine & Public Health Source Type: news

Researchers engineer cells to destroy malignant tumor cells but leave the rest alone
(McMaster University) Researchers at McMaster University have developed a promising new cancer immunotherapy that uses cancer-killing cells genetically engineered outside the body to find and destroy malignant tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 28, 2021 Category: Cancer & Oncology Source Type: news

Anti-cancer immunotherapy drug with reduced side effects and increased therapeutic effects
(National Research Council of Science& Technology) To tackle this issue, a research team led by Dr. Ju Hee Ryu of the Center for Theragnosis at the Korea Institute of Science and Technology (KIST) has developed an anti-cancer prodrug that can improve anti-cancer immunotherapy by reacting only with cancer cells, thereby minimizing the toxicity to normal cells, including immune cells, and boosting patient immunity. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 28, 2021 Category: International Medicine & Public Health Source Type: news

Blood stem cells make brain tumors more aggressive
(German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)) Blood stem cells make brain tumors more aggressiveFor the first time, scientists from the German Cancer Consortium (DKTK) partner site in Essen/D ü sseldorf have discovered stem cells of the hematopoietic system in glioblastomas, the most aggressive form of brain tumor. These hematopoietic stem cells promote division of the cancer cells and at the same time suppress the immune response against the tumor. This surprising discovery might open up new possibilities for developing more effective immunotherapies against these malignant brain tumors. (S...
Source: EurekAlert! - Cancer - June 28, 2021 Category: Cancer & Oncology Source Type: news

Key Presentations on Advanced NSCLC From ASCO 2021 Key Presentations on Advanced NSCLC From ASCO 2021
Dr Mark A. Socinski highlights studies on advanced NSCLC from ASCO 2021, including data on combination immunotherapy, immune adverse events, and response to sotorasib.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 25, 2021 Category: Consumer Health News Tags: None ReCAP Source Type: news

Improving Cancer Immunotherapy with Anti-Cancer Adenoviruses
Researchers use a mesenchymal stromal cell-based vector to deliver multiple viruses simultaneously to improve CAR-T cell anti-tumor activity. (Source: The Scientist)
Source: The Scientist - June 25, 2021 Category: Science Tags: The Marketplace Source Type: news

Mayo Clinic researchers study potential new CAR-T cell therapy for multiple myeloma
ROCHESTER, Minn. -- Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma. Their findings were published on Friday, June 24, in The Lancet."CAR-T cell therapy is a type of immunotherapy that involves harnessing the power of a person's own immune system by [...] (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - June 25, 2021 Category: Hospital Management Source Type: news

Many cancer patients may need a sequential one-two punch of immunotherapies
(La Jolla Institute for Immunology) New research led by scientists at La Jolla Institute for Immunology (LJI) and the University of Liverpool may explain why many cancer patients do not respond to anti-PD-1 cancer immunotherapies--also called checkpoint inhibitors.The team reports that these patients may have tumors with high numbers of T follicular regulatory (Tfr) cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 24, 2021 Category: Cancer & Oncology Source Type: news

Immunotherapy may be effective for subset of prostate cancer
(Beth Israel Deaconess Medical Center) Researchers report that about a quarter of localized prostate cancers may demonstrate immunologic traits that would allow a substantial number of patients with prostate cancer to benefit from immunotherapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 24, 2021 Category: Cancer & Oncology Source Type: news

Mayo Clinic Opens Novel Clinical Trial for Mesothelioma
Researchers at the much-acclaimed Mayo Clinic in Rochester, Minnesota, have opened the first clinical trial for mesothelioma patients that combines a recently approved immunotherapy treatment with targeted radiation. Potential for extending survival is there. This single-center phase I clinical trial opens June 24, and is expected to enroll at least 20 participants. It will study the safety and effectiveness of stereotactic body radiation therapy, known as SBRT, when added to the immunotherapy combination of Opdivo and Yervoy. “The reasoning behind this study is that we need to build upon the success we&rsqu...
Source: Asbestos and Mesothelioma News - June 23, 2021 Category: Environmental Health Authors: Lynette Zilio Source Type: news

CU cancer members recognized for contributions to immunotherapy in pediatric cancer
(University of Colorado Anschutz Medical Campus) Three members of the University of Colorado Cancer Center and a longstanding campus supporter are part of a group of more than 200 researchers nationwide who were recognized in April with the Team Science Award from the American Association for Cancer Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 23, 2021 Category: Cancer & Oncology Source Type: news

UCI-led study finds that cancer immunotherapy may self-limit its efficacy
(University of California - Irvine) Cancer immunotherapy involving drugs that inhibit CTLA-4 also activates an unwanted response that may self-limit its efficacy in fighting tumors, according to a new study led by Francesco Marangoni, Ph.D., assistant professor of physiology& biophysics and member of the Institute for Immunology at the University of California, Irvine. Study results are published online in the journal Cell. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 22, 2021 Category: Biology Source Type: news

SFRP2 and PD-1 immunotherapy combination halts osteosarcoma metastasis in model
(Medical University of South Carolina) In a cancer that has not seen new targeted therapies for over 20 years, MUSC Hollings Cancer Center researcher and oncologist Nancy Klauber-DeMore, M.D., is pioneering new discoveries. Using a combination of personal passion and expertise, Klauber-DeMore shifted her knowledge of the pro-angiogenic protein SFRP2 in breast cancer to address the lack of treatment options for patients with aggressive metastatic osteosarcoma. The results of the combination treatment with SFRP2 and PD-1 antibodies in a preclinical model were published in Cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 22, 2021 Category: Cancer & Oncology Source Type: news

In Early Lung Cancer, Immunotherapy Plus Targeted Radiation May Up Response Rate In Early Lung Cancer, Immunotherapy Plus Targeted Radiation May Up Response Rate
Patients with non-small-cell lung cancer may respond more quickly to neoadjuvant durvalumab combined with stereotactic body radiotherapy than to immunotherapy alone, an early industry-funded trial suggests.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - June 21, 2021 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Clinical Trial Shows Benefits of Vinorelbine for Mesothelioma
Mesothelioma specialist Dr. Dean Fennell has strongly endorsed the use of vinorelbine as a second-line treatment for patients with relapsed disease. He was the lead investigator in a recent phase II clinical trial studying the efficacy of vinorelbine for patients whose pleural mesothelioma cancer had progressed after traditional platinum-based chemotherapy. Fennell, who is chair of thoracic and medical oncology at University of Leicester and University Hospitals in the United Kingdom, has based his belief on the multicenter trial involving 154 mesothelioma patients with relapsed disease. “Doctors should now ...
Source: Asbestos and Mesothelioma News - June 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

'Suffocating' cancer: A new headway in melanoma immunotherapy
(Luxembourg Institute of Health) Led by Dr. Bassam Janji, from the Luxembourg Institute of Health, the team used gene editing technologies to show how targeting HIF-1α could not only inhibit tumor growth, but also drive cytotoxic immune cells to the cancer tissue. This discovery provided a valuable new target to make resistant melanomas more vulnerable to available anti-cancer treatments. Their findings were recently published in the reputable Oncogene journal. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 21, 2021 Category: Cancer & Oncology Source Type: news

Patient vest monitors dose after radionuclide therapy
Researchers are developing a radiation tracking vest for patients to wear a...Read more on AuntMinnie.comRelated Reading: Follow-up SPECT/CT scan tracks radionuclide dose SRI gets funding to research radiation relief SNMMI 2020: Radionuclide treatment paves way for immunotherapy IAEA expands SAFRON to support radionuclide therapy SPECT agent could help spot DNA damage from radiotherapy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 18, 2021 Category: Radiology Source Type: news

KaliVir Immunotherapeutics Appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors
Company Bolsters Leadership Team as it Approaches Clinical Development PITTSBURGH, June 17, 2021 -- (Healthcare Sales & Marketing Network) -- KaliVir Immunotherapeutics, Inc., a privately held biotechnology company focused on the discovery and developm... Biopharmaceuticals, Oncology, Personnel KaliVir Immunotherapeutics, vaccinia virus, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 17, 2021 Category: Pharmaceuticals Source Type: news